Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

The goal of this no-profit, multicenter, biological, non-pharmacologic study is to evaluate minimal residual disease (MRD) in patients treated with Azacitidine and Venetoclax according to clinical practice. The main questions it aims to answer are: 1. kinetics of disease response on treatment with Azacitidine and Venetoclax through the evaluation of MRD with both cytofluorimetric and molecular techniques 2. impact of MRD on survival outcomes. To this end, bone marrow samples will be collected at pre-defined time-points during treatment and MRD will be assessed.

NCT Number	NCT06090786
Lead Sponsor	Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions	AML, Adult, Minimal Residual Disease
Enrollment	225 participants
Start Date	2024-07
Primary Completion	2027-07 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2024-04-10